Cancers, Vol. 12, Pages 254: The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness

Cancers, Vol. 12, Pages 254: The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness Cancers doi: 10.3390/cancers12010254 Authors: Blanca Felipe-Abrio Amancio Carnero The MYB binding protein 1A (MYBBP1A, also known as p160) acts as a co-repressor of multiple transcription factors involved in many physiological processes. Therefore, MYBBP1A acts as a tumor suppressor in multiple aspects related to cell physiology, most of them very relevant for tumorigenesis. We explored the different roles of MYBBP1A in different aspects of cancer, such as mitosis, cellular senescence, epigenetic regulation, cell cycle, metabolism plasticity and stemness. We especially reviewed the relationships between MYBBP1A, the inhibitory role it plays by binding and inactivating c-MYB and its regulation of PGC-1α, leading to an increase in the stemness and the tumor stem cell population. In addition, MYBBP1A causes the activation of PGC-1α directly and indirectly through c-MYB, inducing the metabolic change from glycolysis to oxidative phosphorylation (OXPHOS). Therefore, the combination of these two effects caused by the decreased expression of MYBBP1A provides a selective advantage to tumor cells. Interestingly, this only occurs in cells lacking pVHL. Finally, the loss of MYBBP1A occurs in 8%–9% of renal tumors. tumors, and this subpopulation could be studied as a possible target of therapies using inhibitors of mitochond...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research

Related Links:

Despite their small numbers, cancer stem cells play a central role in driving cancer cell growth, chemotherapeutic resistance, and distal metastasis. Previous studies mainly focused on how DNA or histone modif...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Cell Death &Disease, Published online: 26 February 2020; doi:10.1038/s41419-020-2342-2Identifying conserved molecular targets required for cell migration of glioblastoma cancer stem cells
Source: Cell death and disease - Category: Internal Medicine Authors: Source Type: research
Conclusion: These results showed that CD133 expression can be regulated by methylation. Thus, the demethylation of the CD133 promoter may compromise the treatment of lung cancer by inactivating cancer stem cells and/or activating CGAs. PMID: 32090054 [PubMed]
Source: Korean Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Tags: Korean J Thorac Cardiovasc Surg Source Type: research
Authors: Rutkowska A, Stoczyńska-Fidelus E, Janik K, Włodarczyk A, Rieske P Abstract Epidermal growth factor receptor variant III (EGFRvIII) seems to constitute the perfect therapeutic target for glioblastoma (GB), as it is specifically present on up to 28-30% of GB cells. In case of other tumor types, expression and possible role of this oncogene still remain controversial. In spite of EGFRvIII mechanism of action being crucial for the design of small active anticancer molecules and immunotherapies, i.e., CAR-T technology, it is yet to be precisely defined. EGFRvIII is known to be resistant to degradation, but i...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
AbstractBreast cancer (BC) is the most common malignancy in women with a significant increasing incidence during the reproductive life. However, based on the newest anti-cancer molecular targeting drugs, successful treatments lead to the disease healing particularly in young patients, thus refreshing their motherhood programs. However, as effect of the BC treatment, a premature depletion of the ovarian follicle reserve occurs in more than one-third of patients resulting in permanent infertility. To prevent the cancer treatment-related infertility (CTRI), several options are today utilized. Besides the ovary suppression by ...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors associated with high cardiovascular morbidity and variable risk of malignancy. The current therapy of choice is surgical resection. Nevertheless, PCCs/PGLs are associated with a lifelong risk of tumor persistence or recurrence. A high rate of germline or somatic mutations in numerous genes has been found in these tumors. For some, the tumorigenic processes are initiated during embryogenesis. Such tumors carry gene mutations leading to pseudohypoxic phenotypes and show more immature characteristics than other chromaffin cell tumors; they are also ...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
The United States Public Health Service Flag Promotion ceremony for Rear Admiral (RADM) Richard W. Childs, promoted to RADM Upper Half O-8 in January 2020, is being webcast live on 3/27/2020 from Masur Auditorium. Richard Childs, MD serves as the Clinical Director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH). He was commissioned in the USPHS Commissioned Corps as a Lieutenant in 1995 when joined the NCI as an Oncology Fellow. Following fellowship training, he was appointed a tenure-track investigator in the Hematology Branch of the NHLBI where he continues to conduct r...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
Survival outcomes support the benefits of a geriatric assessment for patients age 70 and older with blood cancers who are candidates for hematopoietic stem cell transplants (HSCT).Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Conclusions: Our results provide a transcriptional rationale for the lack of significant therapeutic benefit from temozolomide in patients with recurrent glioblastoma. Our findings imply that the spectrum of potentially effective drugs is likely to differ between newly diagnosed and recurrent glioblastomas and underscore the merits of glioblastoma stem cells as prognostic models for identifying alternative drugs and predicting drug response in recurrent glioblastoma. With the majority of recurrent glioblastomas being inoperable, glioblastoma stem cell models provide the means of compensating for the limited availability of...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In conclusion, we propose the repurposing of benztropine for anticancer research and therapeutics that can suppress tumor progression, CTC, and metastasis of aggressive cancers by reducing key pro-tumorigenic factors.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Physiology | Stem Cell Therapy | Stem Cells